Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Philip Galebach"'
Autor:
Eytan M. Stein, Min Yang, Annie Guerin, Wei Gao, Philip Galebach, Cheryl Q. Xiang, Subrata Bhattacharyya, Gaetano Bonifacio, George J. Joseph
Publikováno v:
Health and Quality of Life Outcomes, Vol 16, Iss 1, Pp 1-12 (2018)
Abstract Background Preference valuations of health status are essential in health technology and economic appraisal. This study estimated utilities for treatment-related health states of acute myeloid leukemia (AML) and disutilities of severe advers
Externí odkaz:
https://doaj.org/article/d237ba30b31c4c1a8cd41e5c026b90bd
Autor:
Alan G. White, J. Bradford Rice, Khurram Jamil, Belinda Lovelace, Philip Galebach, Aneesha Wagh, Kevin M. Korenblat, George J. Wan
Publikováno v:
Current Medical Research and Opinion. 33:1473-1480
This study evaluated the characteristics, healthcare resource utilization (HCRU), and costs, from the payer perspective, of hepatorenal syndrome (HRS) patients covered by commercial and Medicare insurance. Mortality was assessed as a secondary outcom
Autor:
Elyse Swallow, Se Hyun Kim, Dongyeol Lee, R Degun, Karen Stein, Sung Hee Lim, Keunchil Park, Yu Jung Kim, Myung-Ju Ahn, Philip Galebach, Dony Patel, Jong Seok Lee, Andrew Kageleiry, Kyung Ah Yoh, Jie Zhang
Publikováno v:
Asia-Pacific Journal of Clinical Oncology. 13:e239-e245
Aim This study aimed to describe characteristics, treatment patterns and survival among Korean patients diagnosed with locally advanced or metastatic anaplastic lymphoma kinase (ALK)+ non-small cell lung cancer (NSCLC). Methods A retrospective patien
Autor:
Kenneth W. Culver, Philip Galebach, Edmond Bendaly, Alexander R. Macalalad, Anand A. Dalal, Medha Sasane, Rebekah Foster, Iryna Bocharova, Annie Guerin
Publikováno v:
Advances in Therapy. 34:1145-1156
This study aimed to provide the first real-world description of the characteristics, treatments, dosing patterns, and early outcomes of patients with ALK-positive non-small cell lung cancer (NSCLC) who received ceritinib in US clinical practice. US o
Autor:
Philip Galebach, Cheryl Xiang, S Bhattacharyya, Annie Guerin, George J Joseph, Wei Gao, Min Yang, Gaetano Bonifacio, Eytan M. Stein
Publikováno v:
Health and Quality of Life Outcomes, Vol 16, Iss 1, Pp 1-12 (2018)
Background Preference valuations of health status are essential in health technology and economic appraisal. This study estimated utilities for treatment-related health states of acute myeloid leukemia (AML) and disutilities of severe adverse events
Autor:
James Signorovitch, Timothy Vollmer, Allitia DiBernardo, Philip Galebach, Caroline Kelley, Lynn Huynh, Rahul Sasane
Publikováno v:
Neurological Sciences. 37:165-179
Patients with multiple sclerosis (MS) experience varying rates of brain volume (BV) loss ranging from 0.5 to 1.5 % per year. In addition, 66 % of patients with MS experience cognitive impairment, resulting in impact on daily activities. A systematic
Autor:
Roy Nitulescu, Medha Sasane, Jie Zhang, Katherine Dea, Philip Galebach, Alexander R. Macalalad, Heather A. Wakelee, Kenneth W. Culver, Annie Guerin
Publikováno v:
Current Medical Research and Opinion. 31:1587-1597
Limited post-crizotinib treatment options for ALK-positive non-small cell lung cancer (NSCLC) might lead to poor survival and high economic burden.To evaluate real-world treatment patterns, overall survival (OS), and costs following crizotinib discon
Autor:
Kenneth W. Culver, Annie Guerin, Jie Zhang, Eric Q. Wu, John Jarvis, Medha Sasane, Andrew Kageleiry, Philip Galebach, Alexander R. Macalalad, Heather A. Wakelee
Publikováno v:
Cancer Epidemiology. 39:307-312
Introduction Approximately 2–8% of non-small cell lung cancer (NSCLC) patients have rearrangements in the anaplastic lymphoma kinase gene ( ALK ). ALK -targeted therapy is available to patients with tumors known to be ALK +. This chart review study
Autor:
Sarang Abhyankar, Charles Ayas, Yeun Mi Yim, Annie Guerin, Eric Q. Wu, Carolina Reyes, Geoffrey T. Gibney, Geneviève Gauthier, Philip Galebach
Publikováno v:
Cancer Medicine
Brain metastases are a common and serious complication among patients with metastatic melanoma. The selective BRAF inhibitor vemurafenib has demonstrated clinical efficacy in patients with BRAF V600E-mutant melanoma brain metastases (MBM). We examine
Autor:
Alexander R. Macalalad, Philip Galebach, Anand A. Dalal, Rebekah Foster, Medha Sasane, Edmond Bendaly, Kenneth W. Culver, Iryna Bocharova, Annie Guerin
Publikováno v:
Advances in therapy. 34(7)
Crizotinib is recommended as first-line therapy for ALK-positive non-small cell lung cancer (NSCLC), but within a year of treatment initiation many patients develop resistance. With the recent approval of second-generation ALK inhibitors, this study